VIVO Cannabis Inc (OTCMKTS:VVCIF) Begins Trading On The World-class TSE: Ships Cannabis 2.0 Products To Saskatchewan And Manitoba

VIVO Cannabis Inc (OTCMKTS:VVCIF) has begun trading its common shares on the word class Toronto Stock Exchange (TSE) with effective from January 24, 2020. The company will delist it’s from the TSX Venture Exchange. Chief Executive Officer of Vivo, Barry Fishman, said trading of its shares on TSE is a milestone for the company. Trading on TSE attracts a wider audience and improves liquidity for Vivo. It will get access to a large number of institutional investors.

Issues an update on Cannabis 2.0                                                                  

Vivo announced the shipments of cannabis 2.0 products to Saskatchewan and Manitoba provinces from its Canna Farms Facility. The company also expects to fulfill the POs from British Columbia, Alberta, and Ontario.

Initial shipments of Fireside chocolate products

Vivo expects to ship Fireside chocolate products to Manitoba, Alberta, British Columbia, Saskatchewan, and Ontario provinces. It is also planning to ship vape products, and Fireside concentrates on New Brunswick, Ontario, and Alberta provinces from its Valuven facility before the end of Q1 this year.

Fishman said the company expects to sell cannabis 2.0 products in seven provinces by the end of Q1 2020. It marks a significant achievement for the company. The company is pleased with its cannabis 2.0 products and yearns to offer a rich experience of its products to the customers.

CB2 Insights agrees to assist Vivo

CB2 Insights entered a pact to extend support to Vivo to develop global medical products. As per the terms of the multi-phase research and technology accord, CB2 will combine its CDMS (Clinical Data Management Software) and EDC (Electronic Data Capture) tools for a better understanding of the current medical patient registry of Vivo. Both firms will also work together to validate the efficacy and safety of current products.

Chief Executive Officer of CB2, Prad Sekar, said the regulators are putting a greater emphasis on validating clinical cannabis treatments as the industry evolves. It necessitates the validation of clinical cannabis treatments via clinical trials to measure their efficacy and safety. He further said the company will work with the team of Vivo to develop a research strategy with the help of world-class clinical data and support innovations.